www.ijarp.com ISSN 2456-9992 Page: 01-38

International Journal Advanced Research Publications

Research Article

Volume: 02
Issue: 11

QUANTUM COMPUTING IN DRUG DESIGN FUTURISTIC APPROACHES

***Krishna Arekar, Ved Bhalerao**

A/P Wagholi Tal Haveli Dist Pune.

Article Received: 12 October 2026, Article Revised: 01 November r 2026, Published on: 20 November 2026

***Corresponding Author: Krishna Arekar**
A/P Wagholi Tal Haveli Dist Pune.

Doi: https://doi-doi.org/101555/ijarp.5477

ABSTRACT

Quantum computing has emerged, developed rapidly in recent years in the interdisciplinary trenches of academia and industry based on the possibility to process information in fundamentally different ways in turn achieving unprecedented computational power. Based on this groundbreaking development, quantum computing in healthcare has not been addressed to the extent of its potential.

In this survey paper we present the first and systematic perspective on the multiple facets of quantum computing in relation to empower healthcare systems. Mainly focused on the transformational potential of enhancing compute-intensive solutions related to the drug discovery, personalized medicine, DNA sequencing, medical imaging, and operational optimization. Furthermore, by reviewing existing literature while constructing taxonomies across different dimensions of backgrounds/enabling technologies, applications, requirements, architectures, security, open issues, and future research directions, we provide a panoramic perspective of quantum computing paradigm in healthcare. We believe our findings framework whether introducing researchers new to quantum computing and healthcare or more experienced researchers prepare researchers for the current research landscape, presenting opportunities, challenges and future decision-making framework in designing architectures and applications of use in quantum computing in healthcare.

KEYWORDS: Quantum computing, Chemoinformatics, Cryptography, Cognitive Computational capabilities, Computer-Aided Drug Design (CADD), Drug discovery, Artificial Intelligence And Machine Learning.

INTRODUCTION

Quantum computing is on the verge of changing the way drugs are designed by providing new capabilities to simulate molecular interactions and optimize therapeutic approaches, to overcome basic challenges faced by conventional compute approaches in computational chemistry. This novel approach exploits quantum mechanical effects such as superposition, entanglement, and quantum tunneling, which allows for the processing of complex calculations that classical supercomputers have yet to solve. Above all, the introduction and application of quantum computers, will enhance each stage of drug discovery from target discovery, to lead optimization, to predicting drug metabolic fates and drug delivery systems[1].

Quantum computing is also being evaluated for the purpose of molecular docking, a fundamental task in drug design that estimates the orientation and conformation of a ligand to a target protein. This task can be regarded in terms of combinatorial optimization, for which quantum annealing (QA) and variational quantum algorithms (VQAs) can offer improvements. For instance, a quantum molecular docking (QMD) methodology has been formed on QA-inspired algorithms that encode conformations and orientations efficiently relying on binary encodings. VQAs can be relevant too, as types of algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Approximate Optimizer Algorithm (QAOA) are useful in Noisy Intermediate-Scale Quantum (NISQ) that is the present realm of quantum computing in which there are few qubits available and subject to noise[2].

1. QUANTUM COMPUTING IN DRUG DISCOVERY

Quantum computers have the ability to describe molecular interactions at the atomic scale, which, in classical systems, has an enormous computational cost due to the exponential number of possible quantum states. Accurate Modeling of molecular dynamics and chemical reactions is critical to understanding drug mechanism of action and predicting binding affinities. For example, the energy in ground state for small molecules has been demonstrated successfully with superconducting quantum processors, indicating potential major advances in the development of quantum-approached chemistry problems with respect to drug design. This ability is fundamentally important for:

Drug-target binding and affinity prediction: Calculating the detailed dynamic interactions between a drug candidate and its biological target can help identify drug candidates with higher potency or more selective compounds for the corresponding target.

Optimizing lead compounds: The optimization of the chemical structure of drug leads can be simulated using optimized quantum algorithms to improve therapeutic window and reduce off-target effects.

Resolving Complex biological interactions: Quantum computers can be used to resolve complex biological events that necessarily depend on quantum mechanical events to better understand disease mechanisms and mechanistic interventions[7].

Areas in which quantum computing is likely to prove particularly impactful include the following:

Molecular simulation and modelling: Quantum computers are able to simulate the structure of molecules, and their interactions with more accuracy to aid prediction of drug-target binding affinity, and mechanisms of action. For example, multi-microsecond-long all-atom simulations of SARS-CoV-2 Nsp1 were performed that identify the molecular basis for the immune translational shutdown, illustrating not only the power of detailed molecular simulations but their utility[8].

Virtual screening: Quantum computers are able to more accurately predict how candidate drugs interact with their targets within the context of a cellular environment involving thousands of atoms at finite temperature by coupling quantum chemistry to calculations. This will likely enhance virtual screening studies designed and aimed to be informative to scientists when designing drug candidates from large libraries[9].

Optimization problems: Many of the drug design problems can be framed as optimization problems (such as optimal structure based on molecule design, protein folding, optimal synthesis pathways). Quantum metaheuristic optimization inspired algorithms are typically superior to quantum methods, and possibly superior to tack NP-hard problems[10].

ADME-Tox prediction: Quantum algorithms may provide a more accurate prediction of ADME-Tox - absorption, distribution, toxicity and metabolism. Provided they have value in ADME-Tox prediction, this is a key element of determining candidate drug efficacy and safety[11].

Repositioning drugs and designing them from the ground-up: Quantum computing is good at modeling complex interactions and predicting basic properties of medicines, which

can help identify new therapeutic uses for existing medicines (drug repositioning) or create entirely new molecular structures (de novo design)[12].

The broader application of quantum computing for drug discovery is still primarily in the proof-of-concept phase. Quantum hardware remains limited but so far, there is continuous significant investment in quantum software and error correction and modular architecture works are underway. Within the next 10-20 years, quantum supremacy and the construction of full-scale, noise-resistant, quantum computers is expected. Quantum computing will ultimately enable rapid near real-time assessment of risk to financial position and the develop of large biologics with near zero side effects, enabling a profound economic impact[13].

The incorporation of quantum computing will transform drug development by increasing the accuracy and speed of molecular modeling, develop target-ligand binding prediction, optimization of the drug delivery system, and several other unique applications. Such significant computational power will allow for considerably decreased time and cost to get more drugs to market to address medical needs and additional novel therapeutic developments[8].



Figure 1.1: Areas in which quantum computing is likely to prove particularly Impactful in drug design[8].

Core Approaches in Quantum Computing for Drug Discovery

Quantum computing provides new approaches to drug discovery, focused on faster resolution of intricate molecular questions than classical methodologies. The following methods are currently employed or anticipated in drug design.

1. Quantum Chemistry Simulations

Quantum computers are used to simulate the electronic structure and interactions of drug-related molecules and biological targets at the quantum mechanical level. For example, quantum phase estimation and variational quantum eigensolver (VQE) allow for precise estimates of molecular energies, binding affinities, or reaction pathways, which are essential to elucidating potential drug-target interactions[14].

2. Hybrid Quantum-Classical Pipelines

Hybrid pipelines incorporate quantum computing with classical computing to address various drug discovery problems. In this modality, for example, quantum computers are utilized for the most computationally demanding components of a workflow (like covalent bond cleavage or transition state activation energy), with classical computing being used for the remaining execution of the workflow. Hybrid pipelines are especially useful for workflows that predict Gibbs free energy profiles or involve complex covalent interactions[14].

3. Quantum Machine Learning (QML)

Quantum machine learning algorithms are used on large drug discovery datasets for tasks such as the prediction of protein-ligand binding, drug response prediction, and the generative design of molecules[15].

4. Semiempirical Methods and Multiscale Quantum Methods

Semiempirical quantum mechanical (SQM) methods and multiscale methods, i.e., QM/MM methods (in which quantum mechanics is used for the active site and molecular mechanics for the rest), are optimized for the drug discovery process. They are designed to compromise accuracy and computational cost for models applicable to larger biomolecular systems[16].

5. Quantum-Enhanced Molecular Docking and Screening :

Quantum algorithms are in development to enhance molecular docking and virtual screening, allowing for an accurate and efficient assessment of putative drug candidates from large chemical libraries[15].

Table 1.2: Main Quantum Computing Methods in Drug Design.

Method	Application Area	Key Advantage
Quantum chemistry simulations	Molecular energy, binding, reactivity	High accuracy for small systems
Hybrid quantum-classical pipelines	Workflow integration, energy profiles	Scalability, real-world applicability
Quantum machine learning (QML)	Prediction, generative design	Improved accuracy, data efficiency
Semiempirical/multiscale quantum methods	Large biomolecules, active sites	Balance of cost and accuracy

2. CHEMOINFORMATICS

Chemoinformatics is a multifaceted approach that combines different fields including chemistry, computer science and information technology. Department's of chemoinformatics has altered the landscape of drug design and drug discovery through the application of computational approach to model, analyze, interpret, and predict chemical and biological information . Traditional drug discovery is rigorously expensive, time-consuming, with limited flexibility to probe new and novel interactions and activity predictions, which suggests the appropriate use of advanced in silico chemoinformatics . This chemoinformatics approach is appropriate for predictive models. Thus, chemoinformatics methods may improve predictive techniques and help uncover the identification and optimization of drug candidates in a time-efficient fashion[17].

Chemoinformatics is primarily used to manage and analyze large amounts of chemical information that includes, but is not limited to, chemical structures, physicochemical properties or biological activities and is applicable to all phases of drug discovery . Whether it is compound identification, virtual library design, high throughput data mining or computational prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, chemoinformatics plays a role in structuring data and delivering the output in a useful manner[18].

The evolution of computational chemistry and chemoinformatics has led to a rapid growth of translational health research giving researchers more power to analyze larger datasets, to identify promising drug candidates, to predict drug-target interactions, and to design therapy regimens . The drug discovery process generally encompasses some variation of the following stages: target identification, hit identification, hit-to-lead optimization, lead optimization, and conducting development work on a drug candidate . In each of these phases

chemoinformatics also plays a role, thereby increasing efficiency and success rates in drug development[19].

Key Methodologies and Applications of Chemoinformatics in Drug Discovery

1. Target identification and validation: Chemoinformatics is often leveraged in the first phase of identifying potential biological targets for drug candidates. This would include using large dataset of omics data to determine the relationship between genes and diseases and predicting the drug-targetability of genes via omics metadata (e.g., using genome wide association studies (GWAS) datasets). The tools also incorporate automated literature searches using Natural Language Processing (NLP) to efficiently define and analyze the literature for potential targets. For example, out of human proteins, it is estimated around 2,700 of them are drug targets (ex.vention) and utilizing chemoinformatic tools can further leverage the opportunity[19].

2. Virtual screening and hit identification: Virtual screening (VS) is an important chemoinformatic method used to computationally screen large libraries of chemical compounds for subsequent potential drug candidates that may bind to a biological target of interest . The in silico process can save considerable experimental resource time and costs associated with traditional high-throughput screening . Virtual screening employs a multitude of techniques including molecular docking and pharmacophore mapping . On one hand, molecular docking relates to predicting the interaction of a small molecule (i.e., ligand) binding orientation and approximate binding energy to a target protein. On the other hand, pharmacophore mapping can identify relevant chemical components necessarily related to biological activity in order to find similar and potentially active molecules to consider for study[20].The workflow of drug design shows how structure-based and ligand-based approaches both start to converge towards lead discovery and lead optimization. For structure-based design, the process begins with target identification (target validation), ligand preparation, molecular docking, and virtual screening. Conversely, the ligand-based approach starts with pharmacophore modeling and Quantitative Structure-Activity Relationship (QSAR) studies. Ultimately, both of these paths (structure-based and ligand-based) converge in lead discovery, lead optimization, predicting ADMET, molecular dynamics simulations, in vitro testing, in vivo study testing, and clinical trials
[21].

3. Lead Optimization and ADMET Prediction: After confirming activity of the different hit series, lead optimization is the process of improving the parameters of the hits, such as potency, selectivity, and pharmacokinetic profiles. Chemoinformatics can facilitate this process through various methodologies like QSAR (Quantitative Structure-Activity Relationship) and QSPR (Quantitative Structure-Property Relationship) modeling. In particular, QSAR/QSPR modelling establishes a mathematical relationship between the chemical structure of the compounds and their biological activities or properties to enable prediction of activity of new compounds and/or guide the design of improved drug candidates. The use of machine learning approaches in QSAR modelling is becomming increasingly common and adds to the accuracy of these relationships.

Further, in silico ADMET prediction assesses the absorption, distribution, metabolism, excretion, and toxicity of a potential drug candidate early during discovery and will decrease the likelihood of failure later in the research process. Molecular dynamics simulations are also used to study the dynamic characteristics of ligand:target complexes. This can provide insight into the binding mechanism and stability[20].

4. The Integration of Machine Learning and Artificial Intelligence: The rapid expansion of "big data" chemical data from high-throughput screening (HTS) and combinatorial synthesis has also made machine learning (ML) a critical element of chemoinformatics. ML methods can be seen and are used in several applications in the field, including (but not limited to) reaction representation, de novo molecular design, structure determination, descriptor analysis, and chemometrics. Generative models, and especially generative AI, are increasingly used in de novo drug design to create novel molecular structures based on computational models and to optimize seed/lead compounds. This integration of artificial intelligence into drug discovery is expected to greatly increase the probability of success in drug discovery[22].

5. Quantum Chemoinformatics: A developing horizon is the new area of "quantum-chemoinformatics" that uses theoretical chemistry, specifically quantum chemistry (QC) and ab initio molecular dynamics simulations, based descriptors . This concept is a data-driven approach to chemical reaction design and prediction processes that are essential to the fundamental research of drug discovery . While quantum computers are neither commonplace tools nor employed within pharmaceutical processes, there is an anticipated excitement for

their eventual utility to perform accurate and efficient quantum chemical calculations for drug discovery[23].

6. Data Mining and Analysis of Large Datasets: Due to the unprecedented availability of chemical "big data" from high-throughput screening (HTS) and combinatorial synthesis, machine learning (ML) has become an essential instrument to explore chemical information from large and extensive compound databases. In chemoinformatics, ML has been used for reaction representation, molecular design, structure determination, descriptor analysis, and chemometrics. The combination of ML and artificial intelligence (AI) is revolutionizing drug discovery by providing more accurate predictions and by speeding the design of new compounds[24].

Challenges and Future Directions in chemoinformatics:

1. Notwithstanding substantial progress, obstacles still exist. The size of chemical space, or the immense array of theoretical compounds, is a daunting challenge. New techniques, for instance incorporating substructure counts, k-mers, and Daylight-like fingerprints, are emerging to broaden chemical representation and improve discriminative power in many chemoinformatics-related tasks such as drug classification[25].

2. A further challenge is a biological challenge, that of either tumor-initiating cells (or cancer initiating cells) being drug-resistant. This challenge will require some understanding of tumor biology and associated the associated chemistry to develop new anticancer drugs. Chemoinformatics will play an integral part of the process of disentangling such complex biological problems as prediction remains a major goal of biological research[80].

3. The need for chemoinformatics and bioinformatics to work together has led to the concept of biochemoinformatics. BIC focuses on more broad ranging biological and chemical relationships that arise from the enormous amounts of diverse data generated by drug discovery where the extent of the interaction as illustrative of drug mechanism of action (MoA) is key to understanding drug activity
[26].

4. Chemoinformatics is continuously enlarging its range of techniques including generative AI and quantum computing. These technologies aim to faster (and cheaper) generation of new and novel treatment. Chemoinformatics will help lead the shift away from a purely

experimental trial-and-error approach, to a more interactive knowledge-based rational drug discovery process[22].




Figure 2.1: Role of Cheminformatics in the drug discovery process[27].

3. CRYPTOGRAPHY

Cryptography has an important role in contemporary drug discovery, addressing issues of data security, privacy and intellectual property (IP) concerns in a collaborative and resource intensive environment. The pharmaceutical industry has continued to increase reliance on digital technologies in its intellectual property and clinical research process, such as big data analytics, artificial intelligence (AI), and cloud computing, and exploited new vulnerabilities associated with cyberattacks exposing sensitive data or IP. Thus, cryptography in drug discovery remains critical to guarantee confidentiality, integrity and authenticity throughout the drug design pipeline[28].

The drug discovery process is complex, lengthy and has a high resource burden, taking years to complete and incurring significant settings. The process involves target identification and validation, lead discovery and optimization, and preclinical and clinical. Recent advances put greater use of computational methods, bioinformatics, ML and AI to reduce time and increase accuracy in predicting results [29]. The introduction of new disruptive technologies not only creates alternative ways of innovating the drug discovery process but generates subsequent

volumes of sensitive data that require protections against sharing confidentiality to third party collaborators[30].

Types of cryptographic techniques in drug discovery include

1.Symmetric Encryption: This basic method uses one secret key for both encrypting and decrypting data. In drug discovery, symmetric encryption can secure proprietary research data, experimental results, and patient information, whether it is stored or being transmitted. This ensures that only authorized parties with the correct key can access the information[31].

2.Asymmetric Encryption (Public-Key Cryptography): This method uses a pair of keys: a public key for encryption and a private key for decryption. It is important for secure communication and digital signatures in collaborative drug discovery efforts. This allows researchers to exchange information securely and verify the authenticity of data sources across different institutions[35].

3.Hash Functions: Hash functions create a fixed-size string of characters, known as a hash value, from any size of input. They are essential for ensuring data integrity because any change to the original data creates a different hash value. In drug discovery, hash functions can verify the integrity of large datasets, clinical trial results, and intellectual property records. This ensures that the data has not been altered during storage or transmission[31].

4.Homomorphic Encryption (HE): This technique allows computations to be performed directly on encrypted data without decryption. This is particularly useful for drug discovery and enables privacy-preserving data analysis and collaborative research on sensitive medical data. Researchers can analyze molecular structures, genomic data, or patient responses from various sources while keeping the data encrypted. This maintains confidentiality while still allowing the researchers to gain valuable insights for drug development. This is crucial for protecting patient privacy in clinical trials and genetic studies[35].

5.Differential Privacy: This technique improves data privacy by adding a controlled amount of "noise" to datasets. This makes it difficult to identify individual data points while still allowing for accurate overall analysis. In drug discovery, differential privacy protects patient privacy when sharing large-scale medical data for research. It allows statistical trends to emerge without compromising individual identities[35].

6. Blockchain Technology: Although not entirely a cryptographic technique, blockchain relies heavily on cryptographic principles such as hashing and asymmetric encryption to create an unchangeable and distributed ledger. Blockchain offers a secure system for managing sensitive medical data and protecting intellectual property throughout the drug discovery process. It can track the origins of research data, secure clinical trial records, and establish clear ownership of intellectual assets, reducing the risk of misuse or theft[36].

7. Quantum Cryptography (including Quantum Key Distribution - QKD and Post-Quantum Cryptography - PQC): Quantum cloud computing is set to change cryptographic capabilities. QKD uses quantum mechanics to create theoretically unbreakable encryption methods, ensuring very secure communication channels. PQC focuses on developing cryptographic algorithms that resist attacks from future quantum computers, which can significantly threaten current classical cryptographic systems. These future-proof solutions are crucial for protecting sensitive and long-lasting data in drug discovery, especially as quantum computing technology advances[34].




Figure 3.1: Types of Cryptography.

Application of Cryptography in Drug Discovery

Cryptography plays an important role in numerous aspects of drug discovery, particularly in the cases that pertains to sensitive medical and research data.

1. Data confidentiality and integrity: Cryptography ensures that sensitive research data, including patient records, molecular structures, and experimental results, is kept confidential

and protected against unauthorized access or modification. Encryption and decryption techniques are core for protecting data during transmission and storage[31].

2. Privacy-preserving data sharing: Much of drug discovery requires work through collaborations across multiple institutions and thus the sharing of large datasets. Federated Learning (FL) in conjunction with cryptographic techniques such as homomorphic encryption and differential privacy enables privacy-preserving medical data sharing. Homomorphic encryption enables individuals to run computations on encrypted data without decrypting it, meaning researchers can perform analyses on molecular structures and biological data while keeping their proprietary information intact. Differential privacy adds noise to the data in a way that protects individual privacy whilst still allowing for population-level analyses. This is critical to ensuring patient privacy in clinical trials and genetic studies[32].

3. Protection of Intellectual Property: In a globalized research context, the protection of chemical and pharmaceutical IP is essential. As a decentralized computing platform, blockchain technology can improve the protection of sensitive research data and IP through its in-built properties of immutability and cryptographic assurances throughout the data lifecycle including transfer, storage, and use. The facilitation of blockchain-based encryption mechanisms can also assist in quantitative intellectual share determination during cooperative medical research, through secure administration of user data with advanced confidentiality and integrity guarantees[33].

4. Secured Communication within a Digital Ecosystem: As healthcare data become more digitalized and shared and managed over web-based portals and clouds, the management of secured communication becomes more critical. Cryptographic algorithms are being applied to preserve secrecy in transmittance of medical data from sender to receiver, while preventing malicious attempts to steal data by hackers. This has important application to implantable medical devices (IMDs), which are wirelessly connected, whereby cryptographic processes can provide security for confidentiality and information integrity[30].

5. Quantum Cloud Computing: Quantum Cloud Computing is the high impact technological paradigm that will increase ambiguity and ability to offer levels of cryptographic assurance is beyond the current classical standard. Quantum Cloud will facilitate a new wave of breakthrough encryption techniques through quantum key

distribution and post-quantum agile cryptographic algorithms, which will produce high level durability for safeguarding industrial data from future quantum intrusions[34].

4. COMPUTER-AIDED DRUG DESIGN (CADD)

Computer-aided drug design (CADD) has revolutionized the drug discovery and development process, by leveraging computational approaches and high-performance computing resources to discover, develop, and design biologically active compounds. The goal is to accelerate the early onset of chemical development, shape the development process, and increase the effectiveness of bioactive compounds while decreasing the time and expense associated with traditional methods. The term encompasses and describes many computational approaches, including but not limited to virtual screening, molecular docking, quantitative structure activity relationship (QSAR) modeling, pharmacophore modeling, de novo design, lead optimization, and molecular dynamics simulations[3].




Figure 4.1: Flow Chart of Cadd in Drug Discovery.

CADD is generally divided into two approaches: structure-based drug design (SBDD) and ligand-based drug design (LBDD). SBDD is useful when the three-dimensional structure of a biological target (e.g. protein or enzyme) is known. It utilizes structural information to predict potential drug molecules' interactions with the biological target[4]. An integrated CADD workflow usually includes SBDD and LBDD-driven workflows that can lead to lead discovery, lead optimization, and develop ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity)

predictions. All of which cannot be accomplished without their neighbors in the workflow, in silico predictions are generally performed before moving to in vitro and in vivo studies and then on to clinical trials. CADD has proven its value in almost all therapeutic areas, from the design and development of anti-tubercular agents, cancer therapeutics, to antiviral candidates for diseases such as COVID-19[5].

1. SBDD: Structure-based drug design (SBDD) is used in situations where the three-dimensional (3D) atomic structure of the biological target (usually a protein) is known. Knowledge of the exact 3D structure is critical, as this structure allows scientists to see the location of the binding site where a drug (ligand) will bind to the target. The 3D structure of these biological targets will often be determined experimentally by methods such as X-ray crystallography or Nuclear Magnetic Resonance (NMR) spectroscopy. If an experimental structure is not available, homology modeling could be used as a computational method to predict the protein's 3D structure. The main concept behind SBDD is to rationally design or improve ligands that could bind specifically and effectively to the target active or allosteric site[6].

2. LBDD: Ligand-Based Drug Design (LBDD) is an important approach to Computer-Aided Drug Design (CADD) and is used, in particular, when the three-dimensional (3D) structure of the biological target (e.g., protein) is not known, poorly defined, or challenging to obtain experimentally. In the absence of structural information about the biological target, LBDD presents a strong alternative by examining the characteristics of known active ligands that bind to the target. The key assumption of LBDD is that structurally or physicochemically similar ligands which also exhibit biological activity, will share the same factors that contribute to the original ligands binding and biological activity[6].




Figure 4.2: Conventional pathways in structure-based drug design (SBDD) and ligand-based drug design (LBDD) employ distinct methodologies. SBDD centers on target biomolecule structures, while LBDD relies on known ligand characteristics [67].

Application of Computer Aided Drug Design

1. Artificial Intelligence (AI) and Machine Learning (ML): In general, AI and ML systems are progressively incorporating to expedite the whole cycle of new-drug discovery process. They provide great support to the prediction of protein 3D structures, drug-protein interactions, drug activity, as well as in de novo drug design 2633. ML is additionally suitable for drug repurposing, forecasting new therapeutic applications of already existing drugs via similarity of diseases, off-target effects, and drug-network similarity analysis[37].

2. Fragment-Based Drug Discovery (FBDD): FBDD finds small molecular fragments with weak binding to a target, which are further connected or grown to produce efficient drug candidates. CADD is crucial in characterizing fragment linking and growth by AI-guided design[38].

3. Drug Repositioning/Repurposing: Computer Aided Drug Design (CADD) is the key enabler for the identification of new therapeutic applications for existing, approved drugs, a process that tends to be quicker and cheaper than the production of completely new drugs due to the already established safety profiles[39].

4. Quantum Chemical Calculations: Basically, these calculations illuminate the electronic structure of molecules and the reaction mechanisms, which may be very helpful in the drug metabolism and reactivity 3814. Despite the fact that they are still in the early stages, quantum computers appear to be a good choice for performing correct quantum chemical calculations in drug discovery [40].

5. Development of Specialized Software and Databases: The different software platforms and online tools, for instance, those provided by SwissDrugDesign (like SwissADME, SwissDock, SwissSimilarity, SwissTargetPrediction), have been created to help the various CADD processes[41].

5. COGNITIVE COMPUTATIONAL CAPABILITIES

Cognitive computing systems have the ability to assist us in surpassing our restrictions in multiple scenarios. Though we are in the beginning stages of cognitive computing, the following 10 years will be beyond what is achievable with new software and creations [42]. The potential of cognitive computing systems is nearly limitless, its proficiency to execute complicated operations such as NLP, data mining, classification, and knowledge management

operations makes the cognitive computing system the one to perform very refined operations and solve complex questions .as a result of incorporating cognitive computing, healthcare workers can concentrate on more important business-oriented or strategic projects and at the same time they can save a lot of staff time, also the actual detection and resolution time can be reduced [43]. A list of the various features that distinguish cognitive computing systems from conventional programmed computing systems is illustrated[44].

Table 5.1: cognitive computing capabilities.

Sr no.	Capability	Description
1	Understand	Similar to humans, cognitive computing systems understand medical images, natural languages, and other unstructured data, in addition to structured data like hospital EMR and claims/reimbursemen
2	Reason	Cognitive computing systems can reason, grasp underlying concepts, form hypothesis, and infer and extract ideas
3	Learn	With each data point, interaction and outcome, a cognitive computing system develops and sharpens expertise, so it never stops learning.
4	Interact	With the abilities to see, talk and hear, cognitive computing systems naturally interact with humans.

The Impact of Cognitive Computing on Healthcare

Cognitive computing is transforming the way healthcare works. These advanced systems can process enormous volumes of data—learning from it, reasoning through it, and even interacting with healthcare professionals to help create more personalized and effective treatment plans for patients.




Figure 5.2: Impact of cognitive computing on healthcare.

They pull in information from a wide range of sources: insurance claims, clinical records, patient-generated data, medical literature, imaging scans, and individual patient profiles. After analyzing all this, the system generates intelligent insights and offers recommendations based on probabilities—giving doctors a powerful tool to make better-informed decisions.

Core Uses of Cognitive Computing in Healthcare

1. Boosting Diagnostic Capabilities

- Utilizes large-scale medical data—including health records, scans, and genetic information—to uncover subtle trends and irregularities.
- Enables earlier and more precise identification of illnesses than conventional diagnostic methods.

2. Precision-Based Treatment Planning

- Develops customized therapies by factoring in a patient's DNA, lifestyle choices, and clinical background.
- Systems like IBM Watson for Oncology offer cancer treatment suggestions by analyzing global medical data.

3. Smarter Clinical Decision-Making

- Supports healthcare professionals by merging patient data with medical research and guidelines.
- Delivers timely, data-driven insights to assist in clinical judgments.

4. Interpreting Medical Images with AI

- Applies advanced algorithms to read and analyze diagnostic visuals such as MRIs, CT scans, and X-rays.
- Technologies like Google DeepMind Health excel at detecting conditions like diabetic eye disease with high accuracy.

Table 5.3: key points on impact of cognitive computing healthcare.

Sr no.	Impact
1.	Provide timely insights to individuals.
2.	On a proactive basis, identifies patients that are at risk.
3.	Predictions to the patient health requirements along with the cost of care.
4.	Along with medicine personalization, AI also facilitates clinical decisions based on user data.
5.	Verbalizes the recommendations of an activity/intervention according to the probability of success
6.	The patient can be monitored remotely via diverse technologies (ECG mobile, wearable devices) improving patient's engagement, communication with Health personnel, flow of information through different care settings.
7.	NLP powered by Deep Learning allows fast and accurate patient data extraction and contextualization from the wide range of structured and unstructured data sources.
8.	Facilitates the understanding of the relationship between various factors and the population by healthcare professionals.
9.	Researchers can use genomic data for the study, analysis, and development of new therapies.

10.	The scientists created a tool that analyzes the genetic elements of the disease and how the disease interacts with the other parts of the market and with the various human-made and natural factors that affect the health of an individual.
11.	Implement precise and efficient treatments through AI-guided clinical decision support system after evaluating all the factors about a patient.
12.	The machine learning program gathers AI-based image and text processing information by applying the same principles of logic to find the relevant data in a certain image.
13.	As a result of the project, the team started looking for new methods of using ICU data and merging mobile monitoring with EHR for the purpose of giving feedback to students.
14.	Greatly impacts the core of risk-based prediction systems and financial investments in the field of health.
15.	Patients could be assisted in using knowledge about themselves as well as their
16.	Converts unstructured documents into structured data, which helps to improve communication in care settings

6. DRUG DISCOVERY

Developing a new drug from the initial idea to the launch of a finished product is a complex task. It can take 12 to 15 years and cost over $1 billion. The idea for a target can come from various sources, including academic and clinical research and the commercial sector. Building a substantial body of evidence can take many years before selecting a target for an expensive drug discovery program. Once a target is chosen, the pharmaceutical industry, along with some academic centers, has made some early processes more efficient to find molecules with the right traits to become effective drugs. This review will cover key preclinical stages of the drug discovery process. It will discuss the initial target identification and validation, assay development, high throughput screening, hit identification, lead optimization, and finally the selection of a candidate molecule for clinical development[45].

1. Target Identification

A drug target is versatile and includes several biological entities, such as receptors, enzymes, nucleic acids, structural proteins, and transports. These are specific sites on biomolecules in the body where a drug binds to provide the desired therapeutic effect for treating or preventing a specific disease. Because of this, identifying targets is a crucial step in developing a new medicine[46].

In some cases, the development of a new medicine relies on the idea of binding a single ingredient to one target to treat one disease. This is necessary because combining a drug with multiple targets can complicate target identification. However, this is not always the case[47].The latter situation presents possibilities for discovering and developing new drugs, especially with natural products. Natural products have multiple effects because they consist

of various chemical compounds with broad biological activities, allowing them to interact with multiple targets.

Therefore, identifying targets for natural products, such as botanical bioactives, is essential for optimizing existing drugs and speeding up the development of new ones[48]. Still, there has been a bottleneck in further research on using natural products. Many targets for several bioactive molecules remain unknown[49].

For target identification, researchers use data mining of available biomedical data, which greatly improves target identification. More specifically, data mining means using bioinformatics to help identify, select, and prioritize possible disease targets. This data comes from various sources, including publications, patent information in the literature, proteomics, gene expression, compound profiling, and transgenic phenotyping[50].

For example, since the outbreak of coronavirus disease 2019 (COVID-19), research institutions have made significant investments to develop and screen anti-COVID-19 drugs and vaccines. They rely on data mining and bioinformatics to find potential targets and drugs for preventing and treating COVID-19[51].

2. Target validation

Once the target is identified, a full prosecution of the target should follow, meaning it needs to be validated. The validation techniques for the targeted approach involve in vitro and in vivo studies to modify the desired target in patients. While target identification and validation are multi-step processes that hold their own significance, a combined approach to validation is essential because it greatly enhances confidence in the results. Therefore, careful execution of target identification and validation is crucial for lowering attrition rates and avoiding poor effectiveness. Additionally, combining phenotypic and target-based drug discovery methods can lead to the discovery of first-in-class molecules. This can result in more effective, safer, and stronger best-in-class follow-up molecules[52].

In a recent study related to target identification and validation in cancer drug discovery, researchers used an AI-driven screening strategy to find a new anticancer drug, Z29077885, which targets STK33. The AI system used a large database that merged public data with curated information to identify therapeutic patterns among compounds and diseases. For target validation, in vitro and in vivo studies confirmed Z29077885 as an anticancer drug. The researchers investigated its mechanism of action, finding that it induces apoptosis by deactivating the STAT3 signaling pathway and causes cell cycle arrest at the S phase. They

also confirmed that treatment with Z29077885 reduced tumor size and created necrotic areas. This study demonstrates the effectiveness of the target in both in vitro and in vivo models. Furthermore, it confirms the successful application of AI-driven methods for target identification and validation in cancer drug discovery[53].

Stages Of Drug Discovery

Identifying the medical need motivates drug discovery. It considers whether the proposed therapy will improve safety, efficacy, or mechanisms of treatment for patients with the target disease compared to existing options. Setting objectives is crucial. After that, using the right biological method to test related chemicals is essential when answering questions about the effectiveness of current agents[54].

Key next steps include finding a "hit," which means detecting relevant biological activity in a structurally novel molecule. This is followed by preclinical investigation to assess biological activity in an appropriate animal model. We then enhance the biological activity of the tested molecule by preparing structural analogues. Ultimately, we choose an analogue to be the drug development candidate[52]. The toxicity of the drug candidate will be assessed in an appropriate animal model. If it passes all preclinical tests successfully, the gathered data is submitted as the Investigational New Drug Application (IND) to the Food and Drug Administration (FDA) before advancing to clinical trials[55].




Figure 6.1: The Drug Discovery Process[56].

In the clinical trials, the candidate drug first enters Phase I to test toleration in normal human volunteers. Next, Phase II begins to evaluate how effective the drug is and to determine the right dosage for patients with the target disease. Finally, Phase III involves larger trials with a bigger sample size to build a comprehensive database for safety and effectiveness. Even if the drug candidates successfully complete all three phases of clinical trials, only a few (4–7%) are submitted as INDs. This submission includes all research data for review by FDA experts to approve the new medicine for clinical use, as shown in Figure 6.1 [55].




Figure 6.2: Drug Discovery and Development Funnel.

In the "R" discovery phase (research phase), part of the hypotheses that form the project's foundation leads to what is known as "a drug candidate." In the "D" phase (drug development phase), about 1 out of 15 to 25 drug candidates pass efficacy and safety tests in animals and humans to get approved for marketing, as shown in Figure 6.2 [57].

7. ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY.

Artificial intelligence (AI) and its subfield, machine learning (ML), focus on how to enable machines to perform intelligent tasks effectively without being explicitly programmed for them. Recently, AI systems have approached or even surpassed human performance in certain areas, such as game playing and image recognition, but these have mostly been narrow, specialized tasks. Still, AI is now used successfully across many fields and for complex

challenges, including robotics, speech translation, image analysis, logistics, and designing molecules.

Since the 1960s, medicinal chemistry has used AI in different ways and with varying success to design compounds. Supervised learning, which uses labeled training datasets to train models, is widely applied. One common example is the quantitative structure-activity relationship (QSAR) approach, which predicts properties like logP, solubility, and bioactivity for specific chemical structures. On the other hand, unsupervised learning, which does not rely on labeled data, is also popular in medicinal chemistry. Techniques like hierarchical clustering algorithms and principal components analysis are often used to analyze and organize large molecular libraries into smaller groups of similar compounds[62].

AI innovation plays an important role in drug design by improving ML methods and gathering pharmacological data. AI does not depend on theoretical improvements; its real value lies in transforming medical information into useful studies. There are various methods like Random Forest, Naive Bayesian Classification (NBC), Multiple Linear Regression (MLR), Logistic Regression (LR), Linear Discriminant Analysis (LDA), Probabilistic Neural Networks (PNN), Multi-Layer Perceptron (MLP), and Support Vector Machine (SVM) used in the context of ML. To improve feature extraction and generalization, AI advancements apply deep learning techniques to drug design. Additionally, Fig. 3 displays relevant applications that outline the AI processes used to address drug discovery questions in the review. A range of classification and regression methods, such as supervised learning techniques, responds to expectations in continuous or categorical data factors. Unsupervised methods also contribute by building models that support data clustering[58].




Figure 7.1: Role of Artificial intelligence in Drug Discovery.

Machine learning in drug discovery

The use of machine learning is growing in different areas of the pharmaceutical industry, including drug discovery. This growth is leading to improvements across the industry. The increasing number of companies using machine learning as a key part of their business shows its effectiveness. Large pharmaceutical firms are also looking into machine learning methods for drug research and development. Given how capable machine learning is and how useful it is in drug discovery, it is essential to include it in future advancements in this field. The aim is to use high-throughput screening technologies to lessen the cost and complexity of drug discovery. Machine learning may eventually reduce, or even eliminate, the need for live animal testing. These studies prove that machine learning is a highly effective tool in drug discovery[59].

Certain factors related to chemical and biological information are necessary to improve and advance machine learning technologies for drug discovery and development. This data will help design better systems based on insights drawn from it. To collect this data, medicinal features like cellular toxicity, cell structure heterogeneity, animal model efficacy, on-target activity, pharmacokinetic endpoints, microsomal stability, and cytochrome P450 (CYP) inhibition values must be measured using assays[60].




Figure7.2: Machine Learning in Drug Discovery[61].

Above figure shows a simplified cycle of the events involved in implementing machine learning in the pharmaceutical industry, focusing on the development and manufacturing

sectors. It also illustrates how machine learning operates in general. The data includes various components, such as orthogonal data and applicability domain and termination data. This information is fed into a previously designed algorithm that considers model choices, selection functions, and orthogonal computations. The algorithm produces results and offers iterative improvements to the existing methods to enhance efficiency and reliability. The technique is then adjusted, and the cycle continues until a final product is designed and manufactured[61].

Artificial Intelligence In Drug Discovery

Improved computer power and new techniques in AI could change how we discover and develop drugs. At the time of this literature review, the pharmaceutical industry is experiencing a drop in the efficiency of its drug improvement programs alongside rising research and development costs [63]. Recently, there has been a significant increase in the digitalization of information in the pharmaceutical sector; effectively obtaining, examining, and using this information to address complex clinical issues is a current challenge. AI can handle large amounts of information with improved automation. It can also use machine learning algorithms to boost efficiency and productivity. This section discusses the main uses of AI to enhance the drug discovery process[64].

Below figure illustrates how and where AI can be integrated into drug discovery and development processes, as well as the new applications of AI in the pharmaceutical industry. Drug discovery can be broken down into four parts: drug design, polypharmacology, drug repurposing, and drug screening. The primary use of AI is to predict drug properties, which may lessen the need for clinical trials and live study participants, benefiting both financial and ethical aspects. This section reviews studies that support integrating AI into the drug discovery process to improve efficiency, accuracy, and productivity[65].




Figure 7.3: Application of Artificial Inteligence in Drug Discovery.

Examples of AI tools used in drug discovery

1. DeepChem : MLP model that uses a python-based AI system to find a suitable candidate in drug discovery.

2. DeepTox : Software that predicts the toxicity of total of 12 000 drugs .
3. DeepNeuralNetQSAR : Python-based system driven by computational tools that aid detection of the molecular activity of compounds.
4. ORGANIC : A molecular generation tool that helps to create molecules with desired properties
5. PotentialNet : Uses NNs to predict binding affinity of ligands
6. Hit Dexter ML : technique to predict molecules that might respond to biochemical assays
7. DeltaVina : A scoring function for rescoring drug–ligand binding affinity
8. Neural graph fingerprint : Helps to predict properties of novel molecules.




Figure 7.4: Leading pharmaceutical companies and their association with Artificial Intelligence (AI)organizations that are working in fields including oncology, cardiovascular diseases, and central nervous system disorders[66].

8. QUANTUM COMPUTING IN HEALTHCARE

Quantum computing stands out as a revolutionary departure from traditional computing paradigms in that it employs distinct features of quantum mechanics to process information in fundamentally new ways. The basic unit of quantum information is a qubit. Unlike classical bits, qubits can occupy multiple states at the same time through the concept of superposition[68]. This important property allows quantum systems to be processed across multiple computations, and the capacity to perform these computations grows exponentially as more qubits become entangled. Entanglement represents one of the core features of quantum physics and describes a system of qubits in which any physical property of one qubit (for example, its spin, momentum, or position) is instantly linked to another qubit, regardless of distance between the two[69].

Quantum algorithms have significant potential. Shor's algorithm can quickly factor large numbers, and Grover's algorithm improves search capabilities within a database. These tools could potentially change how we encrypt sensitive health data or alter how we search through large datasets in healthcare. Overall, their power comes in solving problems that require complex pattern recognition or a lot of computational power, including biomolecular simulation related to drug discovery[70].

The healthcare sector has already implemented numerous complicated technologies in practice, such as electronic health records (EHR) systems, advanced imaging modalities such as an MRI or CT scanner, and complex bioinformatics platforms for genomics. However, these technologies are intentionally complex and can encounter several challenges—especially with processing large amounts of data and doing so quickly and accurately. For example, EHR systems often encounter challenges with interoperability, which impacts the ability to seamlessly share data across various applications within a healthcare network. Imaging technologies such as MRI or CT scanning have their own challenges related to complexity and data processing, though they can be one of the most illustrative diagnostic tools for healthcare practitioners[72].

This is even more apparent in genomics, where sequencing technology produces large data sets, which require a substantial amount of computation to extract the patterns that are meaningful. Quantum computing potentially addresses these bottlenecks with its ability to process the same data faster and with better accuracy. For example, quantum algorithms could optimize imaging data analysis and decrease the amount of time needed for the

diagnosis while improving precision. In genomics, quantum systems could streamline the process of identifying genetic markers for disease, leading to faster diagnostic processes and improving personalization of therapy[71].

Despite remaining in relative infancy, quantum computing is beginning to see concrete advances in healthcare. The Cleveland Clinic partnered with IBM to develop the Discovery Accelerator, a joint venture aimed at the application of quantum computing in drug design and personalized medicine. On a similar note, Zapata Computing is partnering with pharmaceutical firms to enhance the methodology of clinical trials using a quantum-inspired technique[71].

Research has explored how quantum computing can be integrated into healthcare. For instance, studies show that quantum computing can improve drug discovery by simulating molecular interactions. This could reduce the time and cost of developing new drugs[70]. Other studies focus on using quantum principles to enhance diagnostic processes. This includes improving imaging technologies through faster and more accurate data processing. Several reviews highlight quantum computing's potential to transform personalized medicine. By using quantum algorithms, healthcare providers could tailor treatments to individual patients based on their unique genetic profiles. This could improve treatment effectiveness and reduce side effects. Additionally, quantum computing could help develop new diagnostic tools and techniques, offering more precision in identifying and treating various medical conditions[73].



Figure 8.1: Domains of quantum computing in the healthcare industry.

Quantum computing is especially suited for many compute-intensive tasks in healthcare, particularly within the current connected Internet of Things (IoT) digital healthcare landscape. This landscape includes interconnected medical devices, such as medical sensors, that link to the Internet or the cloud. The significant boost in computational capacity not only helps healthcare IoT but also allows quantum computers to drive major breakthroughs in this field[74].

By moving from bits to qubits, we can enhance pharmaceutical research in healthcare. This includes examining how proteins fold, understanding how molecular structures, like drugs and enzymes, fit together, determining the strengths of binding interactions between a biomolecule, such as a protein or DNA, and its binding partner like a drug or inhibitor, and speeding up the clinical trial process[75].

A few potential applications illustrate this promise. A quantum computer can perform exceptionally fast DNA sequencing, paving the way for personalized medicine. It can also help develop new therapies and medicines through detailed modeling. Additionally, quantum computers have the potential to create effective imaging systems that provide clinicians with improved clarity in real time. They can also tackle complex optimization problems to create an optimal radiation plan that targets cancerous cells while sparing healthy tissue.

Quantum computing is positioned to allow studies of molecular interactions at the most fundamental level, paving the way for drug discovery and medical research. Whole-genome sequencing can be time-consuming, but with qubits, the process and analytics could be completed much faster. Quantum computing has the potential to transform the healthcare system by enabling on-demand computing, redefining security for medical data, predicting chronic diseases, and improving drug discovery.

Challenges and Limitations of Quantum Computing in Healthcare

While quantum computing has great potential to change healthcare with its powerful computational abilities, its integration into the healthcare field comes with major challenges. These challenges include technical issues and ethical and regulatory concerns that need attention to fully make use of quantum technologies in medical settings. One of the main technical challenges in using quantum computing in healthcare is the early stage of quantum hardware. Quantum computers need very specific conditions to work, such as extremely low temperatures and environments nearly free from magnetic and electrical interference. These

needs make quantum computers both costly and complicated to maintain. Additionally, the current generation of quantum computers, known as NISQ (Noisy Intermediate-Scale Quantum) devices, often has high error rates caused by quantum decoherence and noise. This greatly limits their reliability and scalability for practical uses[77].

Quantum error correction is an important research area, but it needs a lot of extra qubits to fix the errors of one qubit. This extra requirement makes it harder to scale quantum systems. Effective error correction methods are crucial for quantum computers to carry out complex calculations reliably. This is especially true in fields like drug discovery and genetic data analysis, where accuracy is vital [72].

The scalability of quantum systems presents another major challenge. Simply adding more qubits doesn't work the same way as adding processors in classical computing. Each new qubit makes the system much more complicated, requiring even better error correction and environmental controls. This complexity turns scaling quantum computers into a tough technical problem that must be solved to unlock their full potential in healthcare applications [79].The challenges of quantum computing in healthcare are shown in Figure 8.2.




Figure 8.2: Challenges And Limitations of Quantum Computing In Healthcare.

FUTURISTIC APPROCH

Quantum computing is a groundbreaking innovation in computing science that has important implications for drug discovery and design by overcoming important limitations of classical computing methods. The classical drug development process has high costs, long timelines, and significant failure rates, mainly due to the complicated nature of molecular interactions and the large area of chemical space. Quantum computing will provide an innovative way to deal with these issues by simulating complex chemical interactions and potentially optimizing drug-target binding with exceptional accuracy and speed through quantum mechanical phenomena, such as superposition and entanglement.

The innovation of quantum computing in drug design stems from its unique ability to precisively perform quantum chemical calculations, which is simply not possible with classical computations, and is paramount to drug candidates to predict their binding and interactions with their desired biological targets . This is especially relevant to drug design, where there are molecular interactions with thousands of atoms happening simultaneously at finite temperatures and in the context of a cellular environment.

The hurdles associated with the innovative and unique applications of quantum computing in the healthcare domain require inter-disciplinary collaboration. By cohesively forming teams of quantum physicists, healthcare professionals, bioinformatics scientists, and computer scientists, it allows the multidisciplinary approach; which is essential to dealing with the unique set of challenges at the interface of quantum computing and healthcare. Collaborative teams can amalgamate domain and field expertise to build upon efficiencies of knowledge of quantum mechanics while also synergistically building support with other academic institutions in health care practice and biomedical research; while also ultimately leading to a pathway for producing more innovative and applicable solutions to the health care dilemmas.

Academy / industry partnerships is a key collaboration; especially to establish partnerships with academic institutions and the healthcare systems to develop a pathway to promote utility of quantum computing in medicine. Promoting knowledge, access to resources and technology, and potentially accelerating the pace of research and development can all impact the advancement of utility for quantum computing in higher education institutions. More specifically, Dhande, Bagchi, and Solenov et al. detail the collaboration of universities and pharmaceutical companies as examples are engaging quantum computing paradigms in the exploration of quantum based pathways for drug discovery and patient health outcome

assessments; ultimately to provide a visual representation of work being exchanged between organizations in the industry.

In a large scoped and perspective, it is now emerging that there is potential for quantum computing to be accessible, engaged and ultimately address trending health dilemmas in develop evident response to health. For example, through collaborative engagements between international countries and collaborators it is conceivable to engage quantum computing in support of public health surveillance and response, outbreak response, and diversification of prevention strategies globally in response to illness; specifically utilizing quantum computing. This in mind can build capacity through sharing quantum computing resources and expertise while also fund these initiatives as a collaborative interfacing panel.

CONCLUSION

In Conclusion, Computer-Aided Drug Design serves as a revolutionary force in contemporary drug discovery, standing at the crossroads of biological complexities and computational expertise. Nonetheless, as CADD moves forward, it faces various challenges that require ongoing refinement, ethical considerations, and the incorporation of a wide range of biological data. Numerous success stories illustrate the concrete effects of CADD on clinical uses, while the integration of Machine Learning enhances predictive abilities, revealing new possibilities. Collaborative networks and international efforts promote equality in drug discovery, reinforcing the value of cooperation. The blending of personalized medicine provides customized solutions, though it carries its own ethical and accessibility concerns. Looking to the future, advancements in quantum computing, immersive technologies, and sustainable chemistry are set to revolutionize the field, calling for a careful balance between innovation and moral accountability. Ethical and regulatory considerations are crucial in steering the responsible advancement of CADD, particularly as it intersects with new technologies and addresses the complexities of the digital age.

REFERENCES

1. Sankranthi NK. Quantum Computing's future role in AI-Driven drug discovery. World Journal of Advanced Research and Reviews [Internet]. 2025c May 17;26(2):1450–8.
2. Li Y, Cui X, Xiong Z, Liu B, Wang BY, Shu R, et al. Quantum Molecular Docking with a Quantum-Inspired Algorithm. J Chem Theory Comput [Internet]. 2024 Jul 29;20(15):6687–94.

3. Sofi MY, Shafi A, Masoodi KZ. Introduction to computer-aided drug design. In: Bioinformatics for Everyone [Internet]. Elsevier; 2022. p. 215–29.
4. Macalino SJY, Gosu V, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Arch Pharm Res [Internet]. 2015 Jul 25;38(9):1686–701.
5. Oli B. Revolutionizing Drug Discovery: A Comprehensive Review of Computer-Aided Drug Design Approaches. IJRASET [Internet]. 2024 Jul 31;12(7):308–17.
6. Sharma V, Wakode S, Kumar H. Structure- and ligand-based drug design. In: Chemoinformatics and Bioinformatics in the Pharmaceutical Sciences [Internet]. Elsevier; 2021. p. 27–53.
7. Gomase VS, Ghatule AP, Sharma R, Dhamane SP. Quantum Computing in Drug Discovery Techniques, Challenges, and Emerging Opportunities. CDDT [Internet]. 2025 Aug 25;22.
8. Orobator ET, Njei TT, Kanu I. Applications of Quantum Computing in Drug Development. JOPIR [Internet]. 2025 Jun 5;3(3):242–52.
9. Santagati R, Aspuru-Guzik A, Babbush R, Degroote M, González L, Kyoseva E, et al. Drug design on quantum computers. Nat Phys [Internet]. 2024 Mar 4;20(4):549–57.
10. Kumar MGV, Paramesh J, Sriram KP, Anbalagan E, Sasikumar S. Exploring the Potential of Quantum Computing for Revolutionary Problem-Solving and Computational Advancements. In: 2024 International Conference on Cybernation and Computation (CYBERCOM) [Internet]. IEEE; 2024. p. 638–43.
11. Singh D. Quantum Computing Assays: Advancing Drug Metabolism Studies and Drug Delivery Design. DMBL [Internet]. 2024 Nov;17(3):99–103.
12. Das IJ, Bhatta K, Sarangi I, Samal HB. Innovative computational approaches in drug discovery and design. In: Advances in Pharmacology [Internet]. Elsevier; 2025. p. 1–22
13. Kulik SP. Quantum Computing: Predictions and Challenges. Bull Lebedev Phys Inst [Internet]. 2023 Dec;50(S12):S1330–40.
14. Kim, Y. et al. Evidence for the utility of quantum computing before fault tolerance. Nature 618, 500–505 (2023).
15. Riaz, F.; Abdulla, S.; Suzuki, H.; Ganguly, S.; Deo, R.C.; Hopkins, S. Accurate Image Multi-Class Classification Neural Network Model with Quantum Entanglement Approach. Sensors 2023, 23, 2753.
16. Bannwarth, C.; Caldeweyher, E.; Ehlert, S.; Hansen, A.; Pracht, P.; Seibert, J.; Spicher,
17. S.; Grimme, S., Extended tight-binding quantum chemistry methods. WIREs Computational

18. Molecular Science 2021, 11 (2), e1493.
19. Ishimwe NH. Advancements and Challenges in Chemoinformatics: From Drug Discovery to Natural Products Research. NIJBAS [Internet]. 2024 Aug 20;5(2):19–23.
20. Xu J, Hagler A. Chemoinformatics and Drug Discovery. Molecules [Internet]. 2002 Aug 30;7(8):566–600.
21. Qureshi R, Irfan M, Gondal TM, Khan S, Wu J, Hadi MU, et al. AI in drug discovery and its clinical relevance. Heliyon [Internet]. 2023 Jul;9(7):e17575.
22. Ojha H, Sethi M, Kakkar R, Sharma M, Saini M, Pathak M. Chem-bioinformatic approach for drug discovery. In: Chemoinformatics and Bioinformatics in the Pharmaceutical Sciences [Internet]. Elsevier; 2021. p. 207–43.
23. Singh DB, Pathak RK. Computational Approaches in Drug Designing and Their Applications. In: Springer Protocols Handbooks [Internet]. Springer US; 2020. p. 95–117.
24. Yoshimori A. Development of drug discovery support system using chemoinformatics and generative AI technology. Folia Pharmacol Jpn [Internet]. 2025 Mar 1;160(2):120–6
25. Satoh H, Steiner VM, Hutter J. "Quantum-Chemoinformatics" for Design and Discovery of New Molecules and Reactions [Internet]. American Chemical Society (ACS); 2024
26. Ghose AK, Herbertz T, Salvino JM, Mallamo JP. Knowledge-based chemoinformatic approaches to drug discovery. Drug Discovery Today [Internet]. 2006 Dec;11(23–24):1107–14.
27. Ali S, Chourasia P, Patterson M. Expanding Chemical Representation with k-mers and Fragment-based Fingerprints for Molecular Fingerprinting. arXiv [Internet]. 2024.
28. Cirinciani M, Da Pozzo E, Trincavelli ML, Milazzo P, Martini C. Drug Mechanism: A bioinformatic update. Biochemical Pharmacology [Internet]. 2024 Oct;228:116078.
29. Basith, Shaherin & Cui, Minghua & Macalino, Stephani Joy & Park, Jongmi & Clavio, Nina Abigail & Kang, Soosung & Choi, Sun. (2018). Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design. Frontiers in Pharmacology. 9. 10.3389.
30. Gomase VS. Cybersecurity, Research Data Management (RDM), and Regulatory Compliance in Clinical Trials. RRCT [Internet]. 2025 Sep 12;20.
31. Mahurkar V. Drug Discovery Using Machine Learning. IJRASET [Internet]. 2025 Mar 31;13(3):1376–80.

32. Jayaprakash J, Dhanasekaran K, Manikandan S, Kanchana A, Akula TR, Singh M. Cryptography And Steganography For Secure Data Transmission In Medical Application. NeuroQuantology 20 (9), 5103, 2022. 2022.
33. Sri PL, Krishna ChN, Sai AD, Roshini Saini. Concealing the Data Using Cryptography. 2023 Third International Conference on Artificial Intelligence and Smart …, 2023. 2023.
34. Yang M, Huang D, Wan W, Jin M. Federated Learning for Privacy-Preserving Medical Data Sharing in Drug Development. ACE [Internet]. 2024 Dec 6;108(1):7–13.
35. Diwan P, Kashyap R, Khandelwal B. Blockchain assisted encryption scheme for intellectual share estimation using medical research data. Concurrency and Computation [Internet]. 2023 Aug 29;36(2).
36. Malviya RK, Abhireddy N, Vankayalapti RK, Sondinti LRK. Quantum Cloud Computing: Transforming Cryptography, Machine Learning, and Drug Discovery. int jour eng com sci [Internet]. 2023 Dec 27;12(12):25980–97.
37. Zhang C. Cryptography Techniques in Medical Data Privacy Protection: Applications and Challenges of Homomorphic Encryption, Differential Privacy, and Blockchain. ACE [Internet]. 2025 Jul 24;178(1):72–8.
38. Bhattacharya S, Saindane D. Intellectual Property Rights and Computer Applications for Pharmaceutical Research and Development. ADCTRA [Internet]. 2021 Aug;8(2):112–24.
39. Liebman M. The Role of Artificial Intelligence in Drug Discovery and Development. Chemistry International [Internet]. 2022 Jan 1;44(1):16–9.
40. Li Q. Application of Fragment-Based Drug Discovery to Versatile Targets. Front Mol Biosci [Internet]. 2020 Aug 5;7.
41. Rawat S, Subramaniam K, Subramanian SK, Subbarayan S, Dhanabalan S, Chidambaram SKM, et al. Drug Repositioning Using Computer-aided Drug Design (CADD). CPB [Internet]. 2024 Feb;25(3):301–12.
42. Bharatam PV. Computer-Aided Drug Design. In: Drug Discovery and Development [Internet]. Springer Singapore; 2021. p. 137–210.
43. Sciences B. [RETRACTED] Computer-Aided Drug Discovery v1 [Internet]. ZappyLab, Inc.; 2022.
44. Hurwitz J, Kaufman M, Bowles A, Nugent A, Kobielus JG, Kowolenko MD. Cognitive computing and big data analytics. Indianapolis: Wiley; 2015 Mar 2.
45. Finch G, Goehring B, Marshall A. The enticing promise of cognitive computing: high-value functional efficiencies and innovative enterprise capabilities. Strategy & Leadership. 2017 Nov 20;45(6):26-33.

46. Coccoli M, Maresca P, Stanganelli L. Cognitive computing in education. DOAJ (DOAJ: Directory of Open Access Journals) [Internet]. 2016 May 1.
47. Kar Dr A. Drug discovery and development process. Pharma Innovation [Internet]. 2019 Jan 1;8(1):936–9.
48. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239–1249.
49. Klessig DF, Tian M, Choi HW. Multiple targets of salicylic acid and its derivatives in plants and animals. Front Immunol. 2016;7:206.
50. Lo Y-C, Senese S, Li C-M, et al. Large-scale chemical similarity networks for target profiling of compounds identified in cell-based chemical screens. PLoS Comput Biol. 2015;11(3):e1004153.
51. Li G, Peng X, Guo Y, Gong S, Cao S, Qiu F. Currently available strategies for target identification of bioactive natural products. Front Chem. 2021;9:761609.
52. Yang Y, Adelstein SJ, Kassis AI. Target discovery from data mining approaches. Drug Discov Today. 2012;17:S16–S23.
53. Tan S, Chen W, Xiang H, Kong G, Zou L, Wei L. Screening druggable targets and predicting therapeutic drugs for COVID-19 via integrated bioinformatics analysis. Genes Genomics. 2021;43:55–67.
54. Kiriiri GK, Njogu PM, Mwangi AN. Exploring different approaches to improve the success of drug discovery and development projects: a review. Future J Pharm Sci. 2020;6(1):1–12.
55. Tran NL, Kim H, Shin C-H, Ko E, Oh SJ. Artificial intelligence-driven new drug discovery targeting serine/threonine kinase 33 for cancer treatment. Cancer Cell Int. 2023;23(1):321.
56. Lombardino JG, Lowe JA. The role of the medicinal chemist in drug discovery—then and now. Nat Rev Drug Discov. 2004;3(10):853–862.
57. Vohora D, Singh G. Pharmaceutical Medicine and translational Clinical Research. Vohora D, Singh G, editors.. London, United Kingdom: Academic Press; 2017 Nov 17.
58. Ghanim, F. (2025). The drug discovery process.
59. Berdigaliyev N, Aljofan M. An overview of drug discovery and development. Future Med Chem. 2020;12(10):939–947.
60. Lavecchia A, Di Giovanni C (2013) Virtual screening strategies in drug discovery: a critical review. Curr Med Chem 20(23):2839–2860.

61. Elbadawi M, Gaisford S, Basit AW. Advanced machine-learning techniques in drug discovery. Drug Discovery Today [Internet]. 2020b Dec 5;26(3):769–77.
62. Bender A, Cortes-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data. Drug Discovery Today [Internet]. 2021 Jan 27;26(4):1040–52.
63. Reker D. Practical considerations for active machine learning in drug discovery. Drug Discovery Today Technologies [Internet]. 2019 Dec 1;32–33:73–9.
64. Butina D. Unsupervised database clustering based on daylight's fingerprint and tanimoto similarity: a fast and automated way to cluster small and large data sets. Journal of Chemical Information and Computer Sciences. 1999 Jul 26;39(4):747-50.
65. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today [Internet]. 2018b Nov 23;24(3):773–80.
66. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discovery Today [Internet]. 2020 Oct 21;26(1):80–93.
67. Kalyane D, Sanap G, Paul D, Shenoy S, Anup N, Polaka S, et al. Artificial intelligence in the pharmaceutical sector: current scene and future prospect. In: Elsevier eBooks [Internet]. 2020. p. 73–107.
68. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. Drug discovery and evaluation: safety and pharmacokinetic assays. 2024 Oct 22:1461-98.
69. Lu W, Zhang R, Jiang H, Zhang H, Luo C. Computer-Aided drug design in epigenetics. Frontiers in Chemistry [Internet]. 2018 Mar 12;6.
70. Tarasov PA, Isaev EA, Grigoriev AA, Morgunov AF: The utilization of perspective quantum technologies in biomedicine. J Phys: Conf Ser. 2020.
71. Padalhin A, Chung P-S, Woo SH : Quantum technology: a beacon of light for next-generation healthcare . Medical Lasers. 2023.
72. Dhande C, Bagchi P: Quantum computing in healthcare and medicines . Somashekhar R, Bagchi P, Jawalkar KS, Dhanalakshmi G, Hill R, Harke SN (ed): Atlantis Press International BV, Dordrecht; 2023.
73. Padalhin A, Chung P-S, Woo SH: Quantum technology: a beacon of light for next-generation healthcare . Medical Lasers. 2023.
74. Giang V: Quantum computing and its applications in healthcare. ODU Under Res Jr. 2023.

75. Heidari N, Olgiati S, Meloni D, Slevin M, Noorani A, Pirovano F, Azamfirei L: A quantum-enhanced precision medicine application to support data-driven clinical decisions for the personalized treatment of advanced knee osteoarthritis: the development and preliminary Validation of precisionKNEE_QNN. Cureus 2024.
76. Devi A V, V K. Enhanced BB84 quantum cryptography protocol for secure communication in wireless body sensor networks for medical applications. Personal and Ubiquitous Computing [Internet]. 2021 Mar 18;27(3):875–85.
77. Zinner M, Dahlhausen F, Boehme P, Ehlers J, Bieske L, Fehring L. Toward the institutionalization of quantum computing in pharmaceutical research. Drug Discovery Today [Internet]. 2021 Oct 22;27(2):378–83.
78. Fedorov, V.V.; Leonov, S.L. Combinatorial and model-based methods in structuring and optimizing cluster trials. In Platform TrialDesigns in Drug Development; Chapman and Hall/CRC: Boca Raton, FL, USA, 2018; pp. 265–286.
79. Flöther FF: The state of quantum computing applications in health and medicine . Research Directions: Quantum Technologies. 2023, 1:10.
80. Tarasov PA, Isaev EA, Grigoriev AA, Morgunov AF: The utilization of perspective quantum technologies in biomedicine. J Phys: Conf Ser. 2020.
81. Shams M, Choudhari J, Reyes K, et al.: The quantum-medical nexus: understanding the impact of quantum technologies on healthcare. Cureus. 2023.
82. Zhou BBS, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov [Internet]. 2009 Oct;8(10):806–23.